Clinical validation of the Tempus xO assay.

ABSTRACT: We have developed a clinically validated NGS assay that includes tumor, germline and RNA sequencing. We apply this assay to clinical specimens and cell lines, and we demonstrate a clinical sensitivity of 98.4% and positive predictive value of 100% for the clinically actionable variants measured by the assay. We also demonstrate highly accurate copy number measurements and gene rearrangement identification.

SUBMITTER: Beaubier N 

PROVIDER: S-EPMC5995233 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature